VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ETON
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ETONEton Pharmaceuticals, Inc.
$61.99$1.7B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksETONBalance Sheet

Eton Pharmaceuticals, Inc. (ETON) Balance Sheet

9Y historyFree accessUpdated daily

Total assets grew to $157.3M and equity to $86.9M in 2026Q3 with a current ratio of 1.79 and debt-to-equity of 0.28, though debt-to-equity has swung between 0.14 and 1.28 over the period, warranting monitoring.

Income StatementBalance SheetCash FlowRatios

ETON Balance Sheet

Annual statement

ETON Balance Sheet

Eton Pharmaceuticals, Inc. (ETON) balance sheet — 9-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17
Total Current Assets96.78M60.58M41.02M26.84M20M23.6M24.7M15.01M27.5M13.29M
Cash & Short-Term Investments55.63M25.94M14.94M21.39M16.3M14.41M21.3M12.07M26.73M13.16M
Cash Only55.63M25.94M14.94M21.39M16.3M14.41M21.3M12.07M26.73M13.16M
Short-Term Investments0000000000
Accounts Receivable26.43M11.76M5.36M3.41M1.85M5.47M48K473K00
Days Sales Outstanding49.4753.6750.1639.3531.8191.47449.23180.03--
Inventory11.08M15.42M15.23M911K557K550K1.24M380K00
Days Inventory Outstanding107.19151.25356.3931.4329.3276.531.59K306.18--
Other Current Assets07.46M5.49M01.29M001M00
Total Non-Current Assets60.49M31.53M35.1M4.9M5.03M3.86M1.62M2.06M825K151K
Property, Plant & Equipment1.4M636K209K150K260K219K1M1.28M773K119K
Fixed Asset Turnover135.08x125.71x186.66x210.95x81.73x99.69x0.04x0.75x--
Goodwill0000000000
Intangible Assets44.28M30.88M34.88M4.74M4.75M3.62M575K725K00
Long-Term Investments0000000000
Other Non-Current Assets64K19K12K12K12K21K40K61K52K32K
Total Assets157.27M92.11M76.12M31.74M25.03M27.46M26.32M17.07M28.33M13.44M
Asset Turnover1.22x0.87x0.51x1.00x0.85x0.79x0.00x0.06x--
Asset Growth %101.67%21.01%139.83%26.81%-8.87%4.35%54.16%-39.73%110.72%-
Total Current Liabilities54.09M38.49M19.95M16.24M6.46M4.56M3.79M1.96M2.02M793K
Accounts Payable16.5M10.98M4.17M1.85M1.77M1.77M2.34M575K1.42M539K
Days Payables Outstanding116.11107.6797.563.7592.97246.862.99K463.38.23K15.13K
Short-Term Debt11.84M8.79M76K5.38M1.03M1.42M280K000
Deferred Revenue (Current)0000000-133K00
Other Current Liabilities5M015.66M0000133K00
Current Ratio1.79x1.57x2.06x1.65x3.10x5.18x6.51x7.65x13.59x16.76x
Quick Ratio1.58x1.17x1.29x1.60x3.01x5.06x6.18x7.45x13.59x16.76x
Cash Conversion Cycle40.5597.26309.057.02-31.84-78.86-957.1722.91--
Total Non-Current Liabilities16.25M27.47M31.75M22K5.49M5.28M6.86M4.56M1.42M520K
Long-Term Debt11.23M21.77M29.81M05.38M5.26M6.76M4.54M00
Capital Lease Obligations2.1M460K107K22K107K15K99K19K00
Deferred Tax Liabilities0000000000
Other Non-Current Liabilities4.01M3.48M1.83M000000520K
Total Liabilities70.35M65.96M51.7M16.26M11.95M9.84M10.66M6.52M2.02M1.31M
Total Debt24.09M31.02M29.99M5.4M6.52M6.7M7.14M4.56M00
Net Debt-31.54M5.08M15.06M-15.99M-9.78M-7.71M-14.15M-7.51M-26.73M-13.16M
Debt / Equity0.28x1.19x1.23x0.35x0.50x0.38x0.46x0.43x--
Debt / EBITDA0.53x7.54x--------
Net Debt / EBITDA-0.69x1.23x--------
Interest Coverage16.42x0.05x-0.90x-0.65x-9.45x-1.88x-30.50x---
Total Equity86.92M26.15M24.43M15.48M13.08M17.63M15.66M10.55M26.3M12.13M
Equity Growth %402.57%7.07%57.83%18.34%-25.82%12.56%48.46%-59.89%116.84%-
Book Value per Share2.610.970.940.600.520.700.750.594.100.69
Total Shareholders' Equity86.92M26.15M24.43M15.48M13.08M17.63M15.66M10.55M26.3M12.13M
Common Stock29K27K27K26K25K25K24K18K18K6K
Retained Earnings-64.11M-112.49M-107.89M-104.07M-103.13M-94.11M-92.16M-64.19M-45.87M-8.64M
Treasury Stock0000000000
Accumulated OCI000000000-19M
Minority Interest0000000000

Key Metrics

Growth RegimeAccelerating
ProfitabilityModerate
Balance SheetAdequate
Cash FlowImproving
Top Statement Risk

Thin margins and leverage

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Balance Sheet Strengthening From Deficit Base

According to reported quarterly figures, ETON's total assets expanded from $31.8M in 2024Q2 to $157.3M in 2026Q3, while equity rose from $13.5M to $86.9M, suggesting the balance sheet is strengthening materially from a small base.

The expansion appears driven by a combination of revenue-generating growth and capital raised or retained, with the accumulated deficit narrowing from roughly -$107.9M to -$64.1M over the same period. The improvement in equity points to real earnings contribution rather than balance sheet engineering alone, though the deficit remains large. Investors should monitor whether retained earnings continue to move toward positive territory, as that would confirm the trajectory is durable.

Leverage Volatile Despite Lower Current Debt

Based on ETON's reported figures, total debt stood at $24.1M in 2026Q3 against $29.0M a quarter earlier, with debt-to-equity fluctuating between 0.14 and 1.28 across the ten reported quarters.

The swings in debt-to-equity appear driven more by equity movements than by a clear deleveraging program, suggesting leverage management is opportunistic rather than structural. Total debt of $24.1M remains meaningful relative to recent quarterly operating cash flow, so debt service capacity depends on sustaining the recent cash inflows. Refinancing terms and maturity schedules are not disclosed in the provided data and warrant further investigation.

Cash Buffer Rebuilt by Recent Inflows

As reported in financial statements, ETON's cash position rose to $55.6M in 2026Q3 from $19.7M in 2026Q1, with the current ratio at 1.79, indicating a liquidity buffer that has improved meaningfully within two quarters.

The current ratio of 1.79 suggests short-term obligations are covered, though the margin of safety is modest relative to total liabilities of $70.3M. The jump in cash appears linked to the strong third-quarter operating inflow, which may not be fully recurring. Investors should monitor whether cash holds above the $50M level in subsequent quarters without reliance on new financing.

Asset Base Shifting Toward Intangibles

Based on EDBL's reported figures, goodwill of $44.3M and net PP&E of only $1.4M suggest ETON's asset base is predominantly intangible and asset-light, with goodwill representing a material share of total assets.

The low PP&E balance is consistent with an outsourced manufacturing model typical of specialty pharmaceutical firms rather than an owned production footprint. Goodwill at roughly 28% of total assets concentrates impairment risk if acquired product revenues fall short of acquisition assumptions. Management's recognition and testing of this goodwill is not detailed in the provided data and should be reviewed against the revenue trajectory.

Equity Quality Improving Through Earnings

According to recent reported figures, ETON's equity grew to $86.9M in 2026Q3 while the accumulated deficit narrowed by about $43.8M since 2024Q2, indicating that earnings rather than dilution appear to be driving the equity build.

The growth in equity relative to the reduction in the deficit suggests recent profitability is contributing to book value, though the trailing ROE of -18.2% indicates the cumulative record is still negative. Share count changes and stock-based compensation are not detailed in the provided data, so the extent of dilution cannot be assessed here. Investors should monitor whether future equity growth continues to come from retained earnings rather than new share issuance.

Quarterly Strength May Mask Fragile Profitability

The strongest bear case is that ETON's recent quarterly cash and earnings strength reflects launch timing and working capital release, while the trailing net margin of -5.8% and ROE of -18.2% show durable profitability has not yet been established.

The sharp swings in quarterly operating cash flow and working capital suggest that the recent balance sheet improvement may partly reflect timing rather than recurring cash generation. Goodwill and the debt load amplify downside if revenue growth decelerates after launch-driven demand normalizes. Investors should treat the strengthened cash position as provisional until several consecutive quarters confirm sustainable conversion of revenue into cash.

ETON — Frequently Asked Questions

Quick answers to the most common questions about buying ETON stock.

What are the total assets of Eton Pharmaceuticals, Inc. (ETON)?

As of 2025, Eton Pharmaceuticals, Inc. (ETON) had total assets of $92.1M including $60.6M in current assets.

How much debt does Eton Pharmaceuticals, Inc. (ETON) have?

Eton Pharmaceuticals, Inc. (ETON) carries total debt of $31.0M, offset by $25.9M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Eton Pharmaceuticals, Inc.?

Eton Pharmaceuticals, Inc. (ETON) has total shareholders' equity (book value) of $26.2M ($0.97 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Eton Pharmaceuticals, Inc.'s current ratio and liquidity?

Eton Pharmaceuticals, Inc. (ETON) reported a current ratio of 1.57x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.